---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133196"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:10:27.852438+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Madrigal announces up to $300M ATM equity offering program with TD Cowen

## Summary
- Company entered into Sales Agreement with TD Cowen to sell up to $300M of common stock via ATM.
- Prior ATM program with Cowen terminated; had generated $225.1M from 1,333,594 shares.
- Filed prospectus supplement registering up to 7,045,385 shares for selling stockholder; Madrigal receives no proceeds.
- Sales may be made through TD Cowen as agent or principal; company not obligated to sell any shares.

## SEC filing metadata
- accession: 0001193125-24-133196
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524133196/0001193125-24-133196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524133196/d815387d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133196
- JSON: https://secwatch.observer/filing/0001193125-24-133196.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133196.txt

## Key facts
- Material Agreements
  MADRIGAL PHARMACEUTICALS, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $300,000,000 (effective 2024-05-07).
  - Action: entry
  - Agreement: atm program
  - Counterparty: TD Securities (USA) LLC
  - Value: up to $300,000,000
  - Effective: 2024-05-07
  source text: On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC, (“TD Cowen”), pursuant to which the Company may issue and sell through or to TD Cowen, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time having an aggregate sales price of up to $300,000,000 (the “ATM Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312524133196/0001193125-24-133196-index.htm
- Material Agreements
  MADRIGAL PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2024-05-07).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Effective: 2024-05-07
  source text: The Sales Agreement replaces and supersedes the prior sales agreement, dated June 1, 2021 and amended on May 9, 2023, between the Company and Cowen and Company, LLC, an affiliate of TD Cowen (the “Prior Sales Agreement”), which was terminated effective upon the entry into the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312524133196/0001193125-24-133196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.